0000950170-24-040302.txt : 20240402
0000950170-24-040302.hdr.sgml : 20240402
20240402165850
ACCESSION NUMBER: 0000950170-24-040302
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240331
FILED AS OF DATE: 20240402
DATE AS OF CHANGE: 20240402
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Roth David
CENTRAL INDEX KEY: 0001599014
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37813
FILM NUMBER: 24815297
MAIL ADDRESS:
STREET 1: C/O SYROS PHARMACEUTICALS, INC.
STREET 2: 620 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Syros Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001556263
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 453772460
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 CAMBRIDGE PARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
BUSINESS PHONE: 617-744-1340
MAIL ADDRESS:
STREET 1: 35 CAMBRIDGE PARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
FORMER COMPANY:
FORMER CONFORMED NAME: LS22, Inc.
DATE OF NAME CHANGE: 20120815
4
1
ownership.xml
4
X0508
4
2024-03-31
0001556263
Syros Pharmaceuticals, Inc.
SYRS
0001599014
Roth David
C/O SYROS PHARMACEUTICALS, INC.
35 CAMBRIDGEPARK DRIVE
CAMBRIDGE
MA
02140
false
true
false
false
Chief Medical Officer
true
Common Stock
2024-03-31
4
M
false
2000
A
2000
D
Common Stock
2024-03-31
4
M
false
13333
A
15333
D
Common Stock
2024-04-01
4
F
false
4732
5.12
D
10601
D
Common Stock
2024-04-02
4
S
false
150
4.9803
D
10451
D
Restricted Stock Units
2024-03-31
4
M
false
2000
0.00
D
Common Stock
2000
4000
D
Restricted Stock Units
2024-03-31
4
M
false
13333
0.00
D
Common Stock
13333
26667
D
Represents shares of common stock received upon vesting of a restricted stock unit award.
Represents shares used to cover tax withholding upon the release of restricted stock units.
The sale was effected pursuant to a trading plan adopted on March 27, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.97 to $5.02, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023.
Represents a restricted stock unit award granted on February 16, 2023. These restricted stock units vest in three equal annual installments commencing on March 31, 2024.
/s/ Todd Rosenthal, as attorney-in-fact
2024-04-02